AKA. A. Klepikova

A. A. Klepikova

*This is an algorithmically generated author record based on publicly available information.

A. A. Klepikova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Features of the diagnostics and surgical treatment of necrotizing enterocolitis

    by Aleksandra S. Gurskaya, Ekaterina V. Ekimovskaya, Rimir R. Bayazitov, Олег Николаевич Наковкин, Сергей Николаевич Зоркин, Elena Yu. Dyakonova, Мария Александровна Сулавко, Инна Викторовна Карнута, Анна Алексеевна Клепикова, Feliks S. Piloyan, et al.

    Introduction. Necrotizing enterocolitis (NEC) is one of the common causes for abdominal surgery in newborns and infants over he first months of life with a high mortality rate (23.5%), increased in case of surgery to 67%. Materials and methods. We compared premature (n = 25) and full-term (n = 22) newborns operated for NEC complications (laparotomy, resection of necrotized sections of the intestine, intestinal stoma). Also, we evaluated the results of treatment of infants with intestinal stoma after surgical NEC (n = 110, groups 1, 2 and 3). Results. Full-term cases with congenital heart defects are at risk of surgical NEC (p < 0.05). Subtotal and total forms of NEC are associated with lethal outcomes up to 100% in both premature and full-term infants. It is necessary to preserve the ileocecal angle; length measuring of the remaining intestine along the mesenteric edge helps to predict further risks: 60 cm and less leads to 80–100% of post-resection short bowel syndrome. Conclusion. NEC in full-term newborns is due to its hypoxic nature and impaired mesenteric perfusion (congenital heart defects). Surgical NEC can occur without typical symptoms (“covered perforation”), the discrepancy between the clinical and radiographic picture may indicate to subtotal or total intestinal necrosis with up to 100% of lethal outcomes.

  • Open Access

    A somatostatin analogue and immunosuppressive therapy in the treatment of complex forms of chyloperitoneum and chylothorax in newborns and infants

    by A. S. Gurskaya, M. A. Sulavko, R. R. Bayazitov, И. Ви. Карнута, E. V. Ekimovskaya, O. N. Nakovkin, D. M. Akhmedova, A. A. Klepikova, R. A. Khagurov, N. V. Petrova, et al.

    Chyloperitoneum and chylothorax are rare conditions with high mortality rates whose optimal treatment strategy remains unclear. The aim of the study was to evaluate the results of chyloperitoneum and chylothorax treatment with a synthetic somatostatin analogue (octreotide) and immunosuppressive therapy with sirolimus. The study was approved by the Independent Ethics Committee and the Scientific Council of the National Medical Research Center for Children’s Health of Ministry of Healthсare of Russia. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications. We conducted a retrospective study of nine children diagnosed with congenital chyloperitoneum and chylothorax who had been treated from 2018 to 2022. All the children received either abdominal or pleural drainage, parenteral nutrition, and conservative therapy with drugs. The first line of therapy was octreotide for 14–20 days that was then switched to sirolimus if there had been no effect. The effectiveness of conservative therapy with octreotide at a dose of 5–10 µg/kg/hour was observed in 5 cases. If there had been no effect by day 14, the patients were started on sirolimus at a dose of 0.05–0.2 mg/day which proved to be effective in all the patients (n = 4). Our study showed that sirolimus is effective in complex cases of chyloperitoneum and chylothorax in newborns and infants. Because of the rarity of these disorders, our conclusions were based on the analysis of a small cohort. To confirm our results and develop uniform diagnostic and treatment guidelines, further, more targeted multicenter research is needed. Until such guidelines are adopted, decisions on the treatment of chyloperitoneum and chylothorax should be made on an individual basis and approved by the medical committee of a treatment center.